News

Ghanaian scholar earns global recognition for groundbreaking health research
Ghanaian public health researcher Gifty Aboagye-Mensah is making significant strides in the field of international academia, ...
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics Inc. Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the ...
Science X Network8h
Pennington Biomedical Researchers to Present at NUTRITION 2025 Conference in Orlando
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...
Palvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 pa ...